根治性同步放化疗治疗的IIIA/B期鳞状细胞肺癌患者治疗前肿瘤空洞的发生率及其对生存结局的影响
该回顾性分析纳入789例接受根治性同步放化疗的IIIA/B期鳞状细胞肺癌患者,治疗前肿瘤空洞发生率为12%,且与吸烟史、体重下降>5%和咯血显著相关。中位随访22.9个月时,全组中位总生存期、局部区域无进展生存期和无进展生存期分别为23.7、14.7和10.7个月。多因素分析显示,肿瘤空洞与较差的总生存期、局部区域无进展生存期和无进展生存期独立相关。
要点
- 治疗前肿瘤空洞发生于12%的IIIA/B期鳞状细胞肺癌患者。
- 肿瘤空洞与吸烟史、体重下降>5%和咯血显著相关。
- 肿瘤空洞与较差的总生存期、局部区域无进展生存期和无进展生存期独立相关。
核心结论
- 治疗前肿瘤空洞发生于12%的局部晚期鳞状细胞肺癌患者,且与根治性同步放化疗后较差的无进展生存期、局部区域无进展生存期和总生存期结局强烈相关。
研究设计与样本
- 回顾性分析789例接受同步放化疗的IIIA/B期鳞状细胞肺癌患者,放疗剂量60至66 Gy,期间接受1至3周期铂类双药化疗。
- 主要终点为治疗前肿瘤空洞状态与总生存期的关联,次要终点包括局部区域无进展生存期、无进展生存期及肿瘤空洞发生率和相关因素。
主要发现
- 治疗前肿瘤空洞发生于95例患者(12%),在有吸烟史者中为12.6% vs 3.9%(P < .001),在体重下降>5%者中为20.9% vs 7.1%(P < .001),在咯血者中为27.1% vs 6.4%(P < .001)。
- 有和无肿瘤空洞患者的急性和晚期毒性发生率相似(各项P > .05)。
- 全组中位随访22.9个月(范围2.4-71.1个月),中位总生存期、局部区域无进展生存期和无进展生存期分别为23.7、14.7和10.7个月。
- 多因素分析显示,IIIB期疾病(P < .001;HR 1.33;95%CI 1.21-1.45)、体重下降>5%(P < .001;HR 2.10;95%CI 1.85-2.35)、贫血(P < .001;HR 1.82;95%CI 1.67-1.97)和存在肿瘤空洞(P < .001;HR 1.54;95%CI 1.37-1.71)似乎与较差的总生存期独立相关。
- 上述各协变量亦分别与局部区域无进展生存期和无进展生存期独立相关(各项P < .001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the incidence and influence of tumor cavitation (TC) on survival outcomes of locally advanced squamous cell lung cancer (LA-SqCLC) patients treated with concurrent chemoradiation therapy (C-CRT). METHODS AND MATERIALS: Records of 789 stages IIIA/B squamous cell lung cancer (SqCLC) patients treated with C-CRT who received 1 to 3 cycles of platinum-based doublet chemotherapy during 60 to 66 Gy radiation therapy (RT) were analyzed retrospectively. Primary endpoint was the association between overall survival (OS) and pretreatment TC status. Secondary endpoints included locoregional progression-free survival (LRPFS), progression-free survival (PFS), and incidence of TC and correlated factors. RESULTS: Pretreatment TC occurred in 95 patients (12%), being significantly more common in those patients with ever-smoking history (12.6% vs 3.9%; P < .001), weight loss >5% (20.9% vs 7.1%; P < .001), and hemoptysis (27.1% vs 6.4%; P < .001). Rates of acute and late toxicities were similar in patients who presented with and without TC (P > .05 for each). For the whole cohort, at a median follow-up of 22.9 months (range: 2.4-71.1), the respective median OS, LRPFS, and PFS estimates were 23.7, 14.7, and 10.7 months. In multivariate analysis, stage IIIB disease (P < .001; hazard ratio [HR]: 1.33; 95% CI: 1.21-1.45), weight loss >5% (P < .001; HR: 2.10; 95% CI: 1.85-2.35), anemia (P < .001; HR: 1.82; 95% CI: 1.67-1.97), and presence of TC (P < .001; HR: 1.54; 95% CI: 1.37-1.71) appeared to be independently associated with poorer OS durations, likewise the LRPFS (P < .001 for each of these covariates), and PFS (P < .001 for each of these covariates), respectively. CONCLUSIONS: Present results showed that the TC occurred in 12% of LA-SqCLC patients, which was strongly associated with poorer PFS, LRPFS, and OS outcomes after definitive C-CRT.
引用
- Topkan E, Selek U, Ozdemir Y, et al. Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 29887509. doi:10.1016/j.ijrobp.2018.04.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。